ROCK2-IN-13

ROCK2-IN-13 is a selective ROCK2 inhibitor. ROCK2-IN-13 reduces nuclear expression by disrupting the interaction of ROCK2 with transcriptional co activators p300> and PGC 1α, repressing oncogenic transcription. ROCK2-IN-13 activates FOXO1 driven PTEN expression, leading to suppression of the PI3K/Akt pathway, induction of G2/M cell cycle arrest, and promotion of apoptosis. ROCK2-IN-13 ablates the nuclear transcriptional function of ROCK2 that sustains oncogenic signaling and restores the tumor suppressive PTEN/FOXO1 axis. ROCK2-IN-13 can be used for prostate cancer reseach[1].

Product Specifications

UNSPSC

12352005

Target

Akt; Apoptosis; Epigenetic Reader Domain; FOXO; PI3K; PTEN; ROCK

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; Epigenetics; Metabolic Enzyme/Protease; PI3K/Akt/mTOR; Stem Cell/Wnt; TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

N#CC1=CC=C(C=C1C(F)(F)F)NC(NC2=CC=C3C=NC=CC3=C2)=S

Molecular Formula

C18H11F3N4S

Molecular Weight

372.37

References & Citations

[1]Lee J, et al. Inhibition of nuclear ROCK2 by a novel thiourea derivative induces potent antitumor effects through PTEN/FOXO1 pathway restoration in prostate cancer. Bioorg Chem. 2025 Dec;167:109211.